title: Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure.
abstract: Gemcitabine is an intravenously administered nucleoside analog chemotherapeutic agent. The ability to deliver this agent as an oral drug would allow greater flexibility of administration and patient convenience; however, attempts have been fraught with high first-pass metabolism and potential intestinal toxicity. Alternatively, an amide prodrug of gemcitabine (LY2334737) was discovered, which is able to avoid the extensive first-pass metabolism that occurs following administration of gemcitabine. Preclinical in vitro and in vivo experiments were conducted to evaluate the hydrolysis and pharmacokinetics of LY2334737 and its downstream metabolites. In mice, rats, and dogs, the prodrug is absorbed largely intact across the intestinal epithelium and delivers LY2334737 to systemic circulation. The hydrolysis of LY2334737 is relatively slow, resulting in sustained release of gemcitabine in vivo. In vitro experiments identified carboxylesterase 2 (CES2) as a major enzyme involved in the hydrolysis of LY2334737, but with relatively low intrinsic clearance. Following hydrolysis of the prodrug, gemcitabine is cleared predominantly via the formation of its inactive metabolite dFdU. Both biliary and renal excretion was responsible for the elimination of LY2334737 and its metabolites in both mice and dogs.
authors.affiliation: Drug Disposition, Eli Lilly and Company, Indianapolis, IN 46278, USA. enaksha@lilly.com.
authors.forename: Enaksha
authors.initials: E
authors.lastname: Wickremsinhe
authors.forename: Jingqi
authors.initials: J
authors.lastname: Bao
authors.forename: Richard
authors.initials: R
authors.lastname: Smith
authors.forename: Richard
authors.initials: R
authors.lastname: Burton
authors.forename: Shannon
authors.initials: S
authors.lastname: Dow
authors.forename: Everett
authors.initials: E
authors.lastname: Perkins